2013
DOI: 10.4172/2161-105x.s5-001
|View full text |Cite
|
Sign up to set email alerts
|

Long-Term Lung Cancer Survival in a Province of Spain

Abstract: Introduction and aims: To analyze the characteristics and long-term survival of patients diagnosed with lung cancer (LC), small cell and non small cell, in our hospital. Patients and methods:Retrospective study of patients with a cytohistological diagnosis of LC between 1999 and 2004. Survival was estimated using the Kaplan-Meier method. The chi-squared test was used to assess possible associations between different variables.Results: In this time period, 996 cases were diagnosed, 85.6% in males and 14.4% in f… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2013
2013
2013
2013

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 28 publications
(32 reference statements)
0
2
0
Order By: Relevance
“…It is a model based relative measure of the time that it takes for a primary tumor to metastasize to a secondary site, or, roughly speaking, a model based measure of the timescale associated with successful extravasation and colonization (6). Timescales associated with metastatic disease are typically quantified by so-called Kaplan-Meier survival curves (30,31), which follow a cohort of patients from presentation until death, plotting the survival percentage associated with the cohort. Alternative methods have been proposed, but by and large, tracking survival of a cohort of patients remains the industry-standard way of tracking progression.…”
Section: Resultsmentioning
confidence: 99%
“…It is a model based relative measure of the time that it takes for a primary tumor to metastasize to a secondary site, or, roughly speaking, a model based measure of the timescale associated with successful extravasation and colonization (6). Timescales associated with metastatic disease are typically quantified by so-called Kaplan-Meier survival curves (30,31), which follow a cohort of patients from presentation until death, plotting the survival percentage associated with the cohort. Alternative methods have been proposed, but by and large, tracking survival of a cohort of patients remains the industry-standard way of tracking progression.…”
Section: Resultsmentioning
confidence: 99%
“…There has been lack of optimism regarding treatment advances in the last ten years, and progress in treating or predicting the risk for lung cancer has been slow. As highlighted in the article by Lamelas et al [1] in this issue, ongoing efforts to improve the survival of patients with lung cancer should be centered on achieving an earlier diagnosis in addition to developing new targeted or individualized therapies for the disease.…”
mentioning
confidence: 99%